• Je něco špatně v tomto záznamu ?

Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis

B. Brochet, R. Hupperts, D. Langdon, A. Solari, F. Piehl, J. Lechner-Scott, X. Montalban, K. Selmaj, M. Valis, K. Rejdak, EK. Havrdova, F. Patti, N. Alexandri, A. Nolting, B. Keller

. 2022 ; 57 (-) : 103385. [pub] 20211109

Jazyk angličtina Země Nizozemsko

Typ dokumentu klinické zkoušky, fáze IV, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011554

Background Multiple sclerosis (MS) is a chronic disabling disease that is associated with negative effects on health-related quality of life (HRQoL) due to reduced physical and psychosocial functioning. Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) have been approved for the treatment of adult patients with highly active relapsing multiple sclerosis (RMS). The ongoing CLARIFY-MS study (NCT03369665; EudraCT number: 2017-002632-17) aims to assess the effect of cladribine tablets 3.5 mg/kg on HRQoL of patients with highly active RMS. Objective To report on the design of the CLARIFY-MS study, baseline patient characteristics, and results of a pre-planned interim analysis focusing on treatment satisfaction, safety, and tolerability that includes all data reported till 6 months after start of treatment. Methods The CLARIFY-MS study is a 2-year, open-label, single-arm, prospective, multicenter, phase IV study. Eligible patients with highly active RMS were assigned to receive cladribine tablets 3.5 mg/kg over 2 years. Treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM, v1.4; scale range from 0 to 100, higher values indicating higher satisfaction). Safety assessments, including occurrence of treatment-emergent adverse events (TEAEs; any adverse event reported after drug administration), serious adverse events (SAEs), and lymphocyte counts, were summarized descriptively. Results A total of 482 patients from 85 sites in Europe were treated with cladribine tablets. Mean patient age was 37.4 years, 338 (70.1%) were women, median EDSS was 2.5, and 345 (71.6%) were prior users of disease-modifying therapy (DMT). During the first 6 months after the start of treatment, and before reaching the full dose of cladribine tablets, mean TSQM global satisfaction score for the overall population was 70.4 (standard deviation, ± 18.48). The side effects score was 91.9 (± 17.68), convenience scored 86.6 (± 13.57), and effectiveness was 65.8 (± 21.14). A total of 275 patients (57.1%) reported at least one TEAE and 9 patients (1.9%) had a SAE. The majority of observed lymphopenia cases were of grade 1 or 2; 33 (6.8%) of the total study cohort had grade 3 lymphopenia, and no grade 4 lymphopenia was reported. Conclusion Patients reported high treatment satisfaction (TSQM) with cladribine tablets in this pre-planned interim analysis at 6 months. Few serious, and no unexpected, adverse events were reported, and there were no instances of grade 4 lymphopenia over the first 6 months. These preliminary data indicate good tolerability and convenience of administration of cladribine tablets in patients with highly active RMS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011554
003      
CZ-PrNML
005      
20220506131335.0
007      
ta
008      
220425s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.msard.2021.103385 $2 doi
035    __
$a (PubMed)35158476
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Brochet, Bruno $u INSERM U 1215, University of Bordeaux, Bordeaux, France. Electronic address: bruno.brochet@u-bordeaux.fr
245    10
$a Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis / $c B. Brochet, R. Hupperts, D. Langdon, A. Solari, F. Piehl, J. Lechner-Scott, X. Montalban, K. Selmaj, M. Valis, K. Rejdak, EK. Havrdova, F. Patti, N. Alexandri, A. Nolting, B. Keller
520    9_
$a Background Multiple sclerosis (MS) is a chronic disabling disease that is associated with negative effects on health-related quality of life (HRQoL) due to reduced physical and psychosocial functioning. Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) have been approved for the treatment of adult patients with highly active relapsing multiple sclerosis (RMS). The ongoing CLARIFY-MS study (NCT03369665; EudraCT number: 2017-002632-17) aims to assess the effect of cladribine tablets 3.5 mg/kg on HRQoL of patients with highly active RMS. Objective To report on the design of the CLARIFY-MS study, baseline patient characteristics, and results of a pre-planned interim analysis focusing on treatment satisfaction, safety, and tolerability that includes all data reported till 6 months after start of treatment. Methods The CLARIFY-MS study is a 2-year, open-label, single-arm, prospective, multicenter, phase IV study. Eligible patients with highly active RMS were assigned to receive cladribine tablets 3.5 mg/kg over 2 years. Treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM, v1.4; scale range from 0 to 100, higher values indicating higher satisfaction). Safety assessments, including occurrence of treatment-emergent adverse events (TEAEs; any adverse event reported after drug administration), serious adverse events (SAEs), and lymphocyte counts, were summarized descriptively. Results A total of 482 patients from 85 sites in Europe were treated with cladribine tablets. Mean patient age was 37.4 years, 338 (70.1%) were women, median EDSS was 2.5, and 345 (71.6%) were prior users of disease-modifying therapy (DMT). During the first 6 months after the start of treatment, and before reaching the full dose of cladribine tablets, mean TSQM global satisfaction score for the overall population was 70.4 (standard deviation, ± 18.48). The side effects score was 91.9 (± 17.68), convenience scored 86.6 (± 13.57), and effectiveness was 65.8 (± 21.14). A total of 275 patients (57.1%) reported at least one TEAE and 9 patients (1.9%) had a SAE. The majority of observed lymphopenia cases were of grade 1 or 2; 33 (6.8%) of the total study cohort had grade 3 lymphopenia, and no grade 4 lymphopenia was reported. Conclusion Patients reported high treatment satisfaction (TSQM) with cladribine tablets in this pre-planned interim analysis at 6 months. Few serious, and no unexpected, adverse events were reported, and there were no instances of grade 4 lymphopenia over the first 6 months. These preliminary data indicate good tolerability and convenience of administration of cladribine tablets in patients with highly active RMS.
650    _2
$a dospělí $7 D000328
650    _2
$a kladribin $x škodlivé účinky $7 D017338
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x škodlivé účinky $7 D007166
650    12
$a roztroušená skleróza $7 D009103
650    12
$a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a spokojenost pacientů $7 D017060
650    _2
$a osobní uspokojení $7 D010549
650    _2
$a prospektivní studie $7 D011446
650    _2
$a kvalita života $7 D011788
650    _2
$a tablety $7 D013607
655    _2
$a klinické zkoušky, fáze IV $7 D017429
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Hupperts, Raymond $u Zuyderland Medisch Centrum Sittard, Maastricht University Medical Center, Maastricht, the Netherlands
700    1_
$a Langdon, Dawn $u Department of Psychology, Royal Holloway, University of London, Egham, United Kingdom
700    1_
$a Solari, Alessandra $u Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
700    1_
$a Piehl, Fredrik $u Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Lechner-Scott, Jeannette $u University of Newcastle, Newcastle, NSW, Australia; Division of Neurology, John Hunter Hospital, Newcastle, NSW, Australia
700    1_
$a Montalban, Xavier $u Department of Neurology-Neuroimmunology Centre of Multiple Sclerosis of Catalonia (Cemcat), University Hospital Vall d'Hebron, Barcelona, Spain
700    1_
$a Selmaj, Krzysztof $u Center for Neurology, Lodz, Poland
700    1_
$a Valis, Martin $u Charles University and University Hospital, Hradec Králové, Czech Republic
700    1_
$a Rejdak, Konrad $u Medical University of Lublin, Lublin, Poland
700    1_
$a Havrdova, Eva K $u Charles University, First Medical Faculty, Prague, Czech Republic
700    1_
$a Patti, Francesco $u Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania, and Azienda Ospedaliero Universitaria Policlinico "G Rodolico"- San Marco, University of Catania, Catania, Italy
700    1_
$a Alexandri, Nektaria $u Merck Healthcare KGaA, Darmstadt, Germany
700    1_
$a Nolting, Axel $u Merck Healthcare KGaA, Darmstadt, Germany
700    1_
$a Keller, Birgit $u Merck Healthcare KGaA, Darmstadt, Germany
773    0_
$w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 57, č. - (2022), s. 103385
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35158476 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131327 $b ABA008
999    __
$a ok $b bmc $g 1789257 $s 1162752
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 57 $c - $d 103385 $e 20211109 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
LZP    __
$a Pubmed-20220425
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace